Toilet that detects fluorescent drug markers and methods of use thereof
The present disclosure describes a method of detecting a drug marker in urine a urine sample using a toilet. The drug markers are fluorophores each of which emits a unique fluorescence spectra. Accordingly, the method does not detect the drug but rather, the drug marker. The drug marker may include quantum dots which may be functionalized by connecting the quantum dot to a biomolecule. The biomolecule may be cleavable by a peptidase, a protease, or a nuclease to release the drug. Alternatively, the composition may include a liposome carrier. A user who has consumed the drug composition urinates into the toilet and a urine sample is captured. The toilet includes a mechanism for fluid handling which diverts urine into a fluorescence spectrometer. The fluorescence spectrometer screens the urine for drug markers based on their unique fluorescent spectra.
1. A method for detecting at least one drug marker in urine comprising the steps of:
providing a toilet, the toilet comprising:
a urine capture reservoir,
a fluorescence spectrometer, the fluorescence spectrometer comprising:
at least one fluorescence excitation light source,
at least one fluorescence measurement cell, and
a spectral analyzer;
a channel, wherein the channel fluidly connects the urine capture reservoir to the at least one fluorescence measurement cell;
a controller, the controller comprising a non-transitory computer readable medium and, wherein the controller is connected to the fluorescence spectrometer;
depositing a urine sample produced by a user's body into the toilet,
wherein at least a portion of the urine sample enters the urine capture reservoir, travels through the channel, and enters the at least one fluorescence measurement cell,
wherein the user has consumed a composition,
wherein the composition comprises at least one drug, at least one fluorescent drug marker, and a liposome carrier,
wherein the at least one drug is encapsulated within the liposome carrier,
wherein the at least one fluorescent drug markers emits a unique fluorescence emission spectra relative to other fluorescent drug markers when exposed to light of a defined wavelength.
2. The method of claim 1 , wherein the fluorescent drug marker is encapsulated in the liposome carrier.
3. The method of claim 2 , wherein the liposome comprises a ligand, and wherein the ligand targets a tissue in which is a target of the drug.
4. The method of claim 1 , wherein the composition comprises a plurality of drugs.
5. The method of claim 1 , wherein the toilet consists of a device for a deposition of human or animal waste.
6. A method for detecting at least one drug marker in urine comprising the steps of:
providing a toilet, the toilet comprising:
a urine capture reservoir,
a fluorescence spectrometer, the fluorescence spectrometer comprising:
at least one fluorescence excitation light source,
at least one fluorescence measurement cell, and
a spectral analyzer;
a channel, wherein the channel fluidly connects the urine capture reservoir to the at least one fluorescence measurement cell;
depositing a urine sample produced by a user's body into the toilet,
wherein at least a portion of the urine sample enters the urine capture reservoir, travels through the channel, and enters the at least one fluorescence measurement cell,
wherein the user has consumed a composition,
wherein the composition comprises at least one drug, and at least one quantum dot,
wherein the at least one quantum dot is functionalized by coating or connecting the at least one quantum dot to a biomolecule, wherein the biomolecule is cleavable by a peptidase, a protease, or a nuclease,
wherein the at least one quantum dot emits a unique fluorescence emission spectra relative to other fluorescent drug markers when exposed to light of a defined wavelength.
7. The method of claim 6 , wherein the biomolecule is cleavable by a eukaryotic single strand DNA nuclease.
8. The method of claim 7 , wherein the eukaryotic single strand nuclease is selected from the group consisting of a zinc finger nuclease, RNAse H2, pancreatic nuclease, and p53.
9. The method of claim 6 , wherein the biomolecule is cleavable by DNAse I.
10. The method of claim 6 , wherein the biomolecule is cleavable by a eukaryotic protease.
11. The method of claim 9 , wherein the eukaryotic protease is selected from the group consisting of a metalloprotease, a serine protease, a digestive protease.
12. The method of claim 11 , wherein the digestive protease is selected from the group consisting of gastrin, pepsin, trypsin, and chymotrypsin.
13. The method of claim 11 , wherein the serine protease is selected from the group consisting of thrombin, plasmin, and urokinase.
14. The method of claim 6 , wherein the biomolecule is cleavable by a glycoside hydrolase.
15. The method of claim 14 , wherein the glycoside hydrolase consists of lysozyme.
16. The method of claim 6 , wherein the biomolecule is cleavable by an enzyme derived from Escherichia coli.
17. The method of claim 16 , wherein the enzyme derived from Escherichia coli is selected from the group that consists of exonuclease I, exonuclease IV, RNAse A, and RNAse I.
18. The method of claim 6 , wherein the biomolecule comprises a hydrogel.
19. The method of claim 18 , wherein the hydrogel is cleaved by a solution comprising a pH of between about 1.0 and about 3.0.
20. The method of claim 6 , wherein the composition comprises a plurality of drugs.